GlaxoSmithKline (Canada)

Recent papers from GlaxoSmithKline (Canada)

1. Incidence and prevalence of connective tissue disease (CTD)-associated interstitial lung disease in the United StatesClinical Rheumatology · 2026
2. A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid TumorsClinical Cancer Research · 2026
3. Clinical Remission is Achievable for Adult Patients with Severe Asthma Receiving Mepolizumab: A European Retrospective Chart ReviewAdvances in Therapy · 2026
4. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trialGynecologic Oncology · 2026
5. Consistent adherence to biologic therapies is critical for improving outcomes in asthmaJournal of Allergy and Clinical Immunology Global · 2026
6. Antiviral Effect, Safety, and Tolerability of Oral VH4011499, a New Human Immunodeficiency Virus Capsid Inhibitor: Proof-of-Concept TrialClinical Infectious Diseases · 2026
7. Clinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled TrialAdvances in Therapy · 2026
8. Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trialsRespiratory Medicine · 2026
9. Safety and efficacy of dostarlimab monotherapy as first-line treatment in programmed cell death-ligand 1–positive recurrent/metastatic head and neck squamous cell carcinoma: Results from a phase 2 trial.Journal of Clinical Oncology · 2026
10. B32-15 Depemokimab Demonstrates Sustained Long-term Efficacy and Consistent Patient-reported Outcomes Over 2 Years in Patients With Type 2 Asthma: An Integrated Analysis of the SWIFT-1/-2 and AGILE StudiesAmerican Journal of Respiratory and Critical Care Medicine · 2026
11. B22-20 Depemokimab Demonstrates Sustained Long-term Efficacy and Consistent Patient-reported Outcomes Over 2 Years in Patients With Type 2 Asthma and Chronic Rhinosinusitis With Nasal Polyps: An Integrated Analysis of the Phase III SWIFT-1/-2 and the Open-label Extension AGILE StudiesAmerican Journal of Respiratory and Critical Care Medicine · 2026
12. B22-19 Depemokimab Demonstrates Sustained Long-term Efficacy and Consistent Patient-reported Outcomes Over 2 Years in Patients With Type 2 Asthma Irrespective of Baseline Inhaled Corticosteroid Dose: An Integrated Analysis of the Phase III SWIFT-1/-2 and the Open-label Extension AGILE StudiesAmerican Journal of Respiratory and Critical Care Medicine · 2026
13. B58-17 Clinical Characteristics, Disease Burden, and Treatments in Adult Patients With Refractory Chronic Cough/Unexplained Chronic Cough: A Systematic Literature ReviewAmerican Journal of Respiratory and Critical Care Medicine · 2026
14. B32-07 Efficacy and Safety of Twice-yearly Depemokimab in Adolescent Patients With Asthma: Subgroup Analysis of the Swift-1/-2 StudiesAmerican Journal of Respiratory and Critical Care Medicine · 2026
15. Effectiveness of FF/UMEC/VI versus ICS/LABA in Patients with Uncontrolled Asthma Treated in Routine Clinical Practice (PERFORM): A Pragmatic Randomized Controlled TrialJournal of Asthma and Allergy · 2026
16. Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HESJournal of Allergy and Clinical Immunology Global · 2026
17. A Pragmatic RCT of FF/UMEC/VI in Patients with Uncontrolled Asthma: PERFORM ProtocolPulmonary Therapy · 2026
18. Anemia Treatment and Its Clinical Implications in Patients Receiving Hemodialysis Hyporesponsive to Erythropoietin-Stimulating AgentsKidney Medicine · 2026
19. FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up from Dual Therapy Stratified by Exacerbations and Prior Dual Therapy: A Subgroup Analysis of a Comparative Effectiveness StudyAdvances in Therapy · 2026
20. Oral corticosteroid overexposure: characterizing oral corticosteroid use in patients with chronic rhinosinusitis with nasal polypS in Canada (ACTIONS) resultsAllergy Asthma and Clinical Immunology · 2025